### SUPPLEMENTAL MATERIAL

# Ankylosing spondylitis patients present a distinct CD8 T-cell subset with osteogenic and cytotoxic potential

Veronica Martini<sup>1</sup><sup>§</sup>, Ylenia Silvestri<sup>1</sup><sup>§#</sup>, Adrian Ciurea<sup>2</sup>, Burkhard Möller<sup>3</sup>, Gabriela Danelon<sup>1</sup>, Flavio Flamigni<sup>4</sup>, David Jarrossay<sup>1</sup>, Ivo Kwee<sup>1</sup><sup>¶</sup>, Mathilde Foglierini<sup>1</sup><sup>£</sup>, Andrea Rinaldi<sup>5</sup>, Valentina Cecchinato<sup>1</sup><sup>&\*</sup>, Mariagrazia Uguccioni<sup>1</sup><sup>&\*</sup>

#### Affiliations

<sup>1</sup>Institute for Research in Biomedicine, Universitá della Svizzera italiana, Bellinzona, Switzerland <sup>2</sup>Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland <sup>3</sup>Department of Rheumatology and Immunology; Inselspital-University Hospital Bern, University of Bern, Switzerland

<sup>4</sup>Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy <sup>5</sup>Institute for Oncology Research, Universitá della Svizzera italiana, Bellinzona, Switzerland

§ These authors contributed equally to this work

<sup>&</sup> These authors jointly supervised this work

<sup>#</sup> Present address: IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy

<sup>¶</sup>Present Address: BigOmics Analytics SA, Lugano, Switzerland

<sup>£</sup> Present address: Service d'immunologie et d'allergie, CHUV, Lausanne, Switzerland

\*Correspondence to:

Prof. Mariagrazia Uguccioni, Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland

mariagrazia.uguccioni@irb.usi.ch

Dr. Valentina Cecchinato, Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland valentina.cecchinato@irb.usi.ch

Page 1 of 7



Supplemental Figure 1. Differentiation state and effect of TNF treatment on phenotype of CD8<sup>+</sup>CCR4<sup>+</sup> T-cells. (A) Left: Identification of  $T_{EM}$  (purple) and  $T_{EMRA}$  (orange) based on the expression of CD45RA and CCR7 and subsequent analysis of CD27 and CD28 expression in these populations. Right: mean frequencies ± SEM of the expression of CD27 and CD28 by  $T_{EMRA}$  (top) and  $T_{EM}$  (bottom) in CD8<sup>+</sup>CCR4<sup>+</sup> T-cells. (B) Left: Mean frequencies ± SEM of CD8<sup>+</sup> T-cells expressing CCR4 in HD and patients with active AS under treatment with TNF inhibitors (TNFi+) or not treated with TNFi (TNF-). Right panel: memory phenotype frequencies of CD8<sup>+</sup>CCR4<sup>+</sup> T-cells in HD and patients with active AS according to TNFi treatment. (C) Correlation between frequencies of CD8<sup>+</sup>CCR4<sup>+</sup> T-cells with a T<sub>EM</sub> phenotype and ASDAS in patients with active AS under TNFi treatment. Kruskal-Wallis was used to compare frequencies and phenotypes amongst the groups, asterisks indicate significant differences between the groups (\* p<0.05, \*\* p<0.01).

Page 2 of 7



Supplemental Figure 2. Activation and proliferation state of CD8+CCR4+ T-cells. Mean frequencies ± SEM of HLA-DR+ CD38+ (A), PD-1+ (B) and Ki67+ cells (C) in CD8+CCR4+ T-cells.

Page 3 of 7



**Supplemental Figure 3. Cytokine secretion profile in CD8+CCR4+T-cells.** CD8+CCR4+T-cells were sorted and stimulated with PMA and ionomycin for 5 hours. Intracellular cytokine staining was performed and mean frequencies of indicated cytokine secreting cells assessed by flow cytometry. Each symbol represents an individual and Kruskal-Wallis was used to compare markers between the groups, asterisks indicate significant differences between the groups (\*\* p<0.01).

Page 4 of 7

# Supplemental Table 1. List of antibodies used for flow cytometry

Targeted	Fluorochrome	Clone	Isotype	Source
Human Antigen				
CCR4	PE-Cv7	L291H4	Mouse laG1	BioLegend
CCR5	FITC	45523	Mouse IgG2b	R&D Systems
CCR6	PE	11A9	Mouse laG1	BD Biosciences
CCR7	PE-Cv7 /	G043H7	Mouse IgG2a	Biolegend
	Brilliant Violet 421		0	5
CD27	V500	M-T271	Mouse IgG1	<b>BD Biosciences</b>
CD28	PE	CD28.2	Mouse laG1	BioLegend
CD3	APC-Cy7	SP34-2	Mouse IgG1	BD Biosciences
CD38	Brilliant Violet 421	HB-7	Mouse IgG1	BioLegend
CD4	PerCP-Cy5.5	L200	Mouse IgG1	BD Biosciences
CD45RA	FITC	ALB11	Mouse IgG1	Beckman Coulter
CD8	APC	B9.11	Mouse IgG1	Beckman Coulter
CD8	BV786	RPA-T8	Mouse IgG1	BD Biosciences
CD8a	Pacific Blue	HIT8a	Mouse IgG1	BioLegend
CLA1	Brilliant Violet 421	HECA-452	Rat IgM	<b>BD</b> Biosciences
CX3CR1	PE	2A9-1	Rat IgG2b	BioLegend
CXCR3	Alexa Fluor 488 / PE	1C6/CXCR3	Mouse IgG1	BD Biosciences
Granzyme B	Pacific Blue	GB11	Mouse IgG1	BioLegend
HLA-DR	V500	G46-6	Mouse IgG2a	BD Biosciences
IFNγ	FITC	B27	Mouse IgG1	<b>BD Biosciences</b>
IL-2	PerCP-eFluor 710	MQ1-17H12	Rat IgG2a	eBioscience
IL-4	PE	MP4-25D2	Rat IgG1	<b>BD Biosciences</b>
IL-13	Brilliant Violet 421	JES10-5A2	Rat IgG1	BioLegend
IL-17A	Brilliant Violet 605	BL168	Mouse IgG1	BioLegend
IL-22	PerCP-eFluor™	IL22JOP	Rat IgG2a	eBioscience
	710			
IL-23	eFluor™ 660	fc23cpg	Rat IgG1	eBioscience
Integrin β7	PE	FIB504	Rat IgG2a	BioLegend
Ki-67	Alexa Fluor 488	Ki-67	Mouse IgG1	BioLegend
PD-1	Brilliant Violet 785	EH12.2H7	Mouse IgG1	BioLegend
Perforin	APC	B-D48	Mouse IgG1	BioLegend
TNFα	Brilliant Violet 650	Mab11	Mouse IgG1	BioLegend

Page **5** of **7** 

## SUPPLEMENTAL METHODS

## **RNA** sequencing

*Library preparation and sequencing.* The quality of the isolated RNA was determined with a Qubit (1.0) Fluorometer (Life Technologies) and a Fragment Analyzer (Agilent). Only those samples with a 260nm/280nm ratio between 1.8–2.1 and a 28S/18S ratio within 1.5-2 were further processed. NEBNext Ultra Directional RNA Library Prep for Illumina (New England BioLabs Inc.) and the NEBNext Multiplex Oligos for Illumina (New England BioLabs Inc.) kits were then used for library and cDNA synthesis and addition of barcode sequences, as per manufacturer's instruction. The sequencing of the libraries was performed in two batches using the NextSeq 500 (Illumina) with the NextSeq 500/550 High Output Kit v2.5 (75 cycles; Illumina) or with Novaseq 6000 (Illumina). Samples were processed starting from stranded, single-ended 75 bp-long sequencing reads. The sequencing was performed either at the Genomic Facility, Institute for Oncology Research or at the Functional Genomic Centre Zurich.

*Bioinformatics analysis.* RNA sequencing reads were aligned with the STAR-aligner <sup>1</sup>. The Ensembl human genome build GRCh38 was used as reference. Gene expression counts were computed with the function featureCounts from the R package Rsubread <sup>2</sup>. Gene expression analysis was performed using the BigOmics platform <sup>3</sup> (version v2.8.0), after batch correction made with the SVA method <sup>4</sup>. Differential gene expression analysis was computed by the platform using both edgeR and DEseq2 packages <sup>56</sup>. Gene set enrichment analysis was then performed on the obtained gene expression profile for each of the following comparison: active AS vs HD; active AS vs inactive AS; active ASe vs HD using the gene set variation analysis (GSVA) statistical method <sup>7</sup>. Gene Ontology Biological Process (GOBP) was used as a database for the gene set enrichment analysis, FDR<0.05 and | (log(Fold Change)) | >0.2 were set as statistical parameters. Using this approach, we could identify 153 differentially expressed GOBP in the comparison active vs HD (146 upregulated and 7 downregulated); 126 in the comparison active AS (all upregulated) and 144 in the comparison inactive AS vs HD (1 upregulated and 143 downregulated).

#### SUPPLEMENTAL REFERENCES

- 1. Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 2013;29(1):15-21. doi: 10.1093/bioinformatics/bts635 [published Online First: 20121025]
- Liao Y, Smyth GK, Shi W. The Subread aligner: fast, accurate and scalable read mapping by seedand-vote. *Nucleic Acids Res* 2013;41(10):e108. doi: 10.1093/nar/gkt214 [published Online First: 20130404]
- Akhmedov M, Martinelli A, Geiger R, Kwee I. Omics Playground: a comprehensive self-service platform for visualization, analytics and exploration of Big Omics Data. NAR Genom Bioinform 2020;2(1):lqz019. doi: 10.1093/nargab/lqz019 [published Online First: 20191206]
- Leek JT, Johnson WE, Parker HS, et al. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. *Bioinformatics* 2012;28(6):882-3. doi: 10.1093/bioinformatics/bts034 [published Online First: 20120117]

Page 6 of 7

- 5. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 2014;15(12):550. doi: 10.1186/s13059-014-0550-8
- Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* 2010;26(1):139-40. doi: 10.1093/bioinformatics/btp616 [published Online First: 20091111]
- Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNAseq data. *BMC Bioinformatics* 2013;14:7. doi: 10.1186/1471-2105-14-7 [published Online First: 20130116]

Page 7 of 7